Skip to main content
PURE Bioscience, Inc. (PURE)
OTCMKTS · Delayed Price · Currency is USD
0.0700
0.00 (0.00%)
At close: Nov 13, 2026

PURE Bioscience Financials Overview

Millions USD. Fiscal year is Aug - Jul.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJul '26 Jul '26 Jul '25 Jul '24 Jul '23 Jul '22
Revenue
2.322.322.21.961.881.85
Revenue Growth
5.27%5.27%12.17%4.58%1.29%-52.81%
Gross Profit
1.331.331.31.150.971
Operating Income
-2.08-2.08-2.27-3.13-3.63-3.37
Net Income
-2.48-2.48-2.4-3.35-3.96-3.49
Earnings Per Share
-0.02-0.02-0.02-0.03-0.04-0.04
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJul '26 Jul '26 Jul '25 Jul '24 Jul '23 Jul '22
Cash & Investments
0.570.570.330.351.13.39
Total Debt
6.66.65.242.951.02-
Net Cash (Debt)
-6.03-6.03-4.9-2.60.073.39
Net Cash Growth
-----97.82%57.65%
Net Cash Per Share
-0.05-0.05-0.04-0.020.000.04

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJul '26 Jul '26 Jul '25 Jul '24 Jul '23 Jul '22
Operating Cash Flow
-1.74-1.74-2.02-2.53-3.28-2.42
Capital Expenditures
-----0.03-0.08
Free Cash Flow
-1.74-1.74-2.02-2.53-3.31-2.5
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJul '26 Jul '26 Jul '25 Jul '24 Jul '23 Jul '22
Gross Margin
57.20%57.20%59.17%58.69%51.73%53.97%
Operating Margin
-89.86%-89.86%-103.18%-159.50%-193.29%-181.87%
Pretax Margin
-107.12%-107.12%-108.95%-170.66%-211.03%-188.40%
Profit Margin
-107.12%-107.12%-108.95%-170.66%-211.03%-188.40%
FCF Margin
-74.98%-74.98%-91.51%-128.94%-176.40%-134.86%

Valuation
Chart
Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingNov '26 Jul '26 Jul '25 Jul '24 Jul '23 Jul '22
PS Ratio
4.233.594.564.555.0712.00